Cross-sectional study evaluating data quality of the National Cancer Registration and Analysis Service (NCRAS) prostate cancer registry data using the Cluster randomised trial of PSA testing for Prostate cancer (CAP)

Samuel W D Merriel, Emma Turner, Eleanor Walsh, Grace Young, Chris Metcalfe, Luke Hounsome, Isobel Tudge, Jenny Donovan, Freddie Hamdy, David Neal, Richard Martin

Research output: Contribution to journalArticle (Academic Journal)

4 Citations (Scopus)
181 Downloads (Pure)

Abstract

Objectives
To compare the completeness and agreement of prostate cancer data recorded by the National Cancer Registration and Analysis Service (NCRAS) with research-level data specifically abstracted from medical records from the Cluster randomised trial of PSA testing for Prostate cancer (CAP) trial.

Design

Cross-sectional comparison study

Participants

We included 1,356 men from the CAP trial cohort who were linked to the NCRAS
registry.

Primary and secondary outcome measures

Completeness of prostate cancer data in NCRAS and CAP and agreement for TNM
stage (T1/T2; T3; T4/N1/M1) and Gleason grade (4-6; 7; 8-10), measured by
differences in proportions and Cohen’s Kappa statistic. Data were also stratified by year and pre- versus post-2010, when NCRAS reporting standards changed.

Results

Compared to CAP, completeness was lower in NCRAS for Gleason grade (41.2% vs 76.7%, difference 35.5 95% CI 32.1, 39.0) and TNM stage (29.9% vs 67.6%, difference 37.6 95% CI 34.1, 41.1). NCRAS completeness for Gleason grade (pre- versus post-2010 31.69% vs 64%; difference 32.31 95% CI 26.76, 37.87) and TNM stage (19.31% vs 55.50%; difference 36.19 95% CI 30.72, 41.67) improved over time. Agreement for Gleason grade was high (Cohen’s Kappa, κ=0.90 95% CI 0.88, 0.93), but lower for TNM stage (κ=0.41 95% CI 0.37, 0.51) overall. There was a trend towards improved agreement on Gleason grade, but not TNM stage, when comparing pre- and post-2010.

Conclusion

NCRAS case identification was very high, however data on prostate cancer grade was less complete than CAP, and agreement for TNM stage was modest. Although the completeness of NCRAS data has improved since 2010, the higher completeness rate in CAP demonstrate that gains could potentially be achieved in routine registry data. This study’s findings highlight a need for improved recording of stage and grade data in the source medical records.
Original languageEnglish
Article numbere015994
Number of pages6
JournalBMJ Open
Volume7
Issue number11
Early online date14 Nov 2017
DOIs
Publication statusPublished - Nov 2017

Structured keywords

  • BTC (Bristol Trials Centre)

Keywords

  • Cancer
  • Prostate
  • REGISTRY

Fingerprint Dive into the research topics of 'Cross-sectional study evaluating data quality of the National Cancer Registration and Analysis Service (NCRAS) prostate cancer registry data using the Cluster randomised trial of PSA testing for Prostate cancer (CAP)'. Together they form a unique fingerprint.

Cite this